Bevacizumab in Advanced High Grade Serous Ovarian Cancer: The Impact of BRCA Mutation Status

• Marwa Aboalsoud

  Clinical Oncology and Nuclear Medicine Department, Tanta University Hospital, Faculty of Medicine, Tanta University, Tanta, AL Gharbia, Egypt

• Zeinab Fathy Abdallah

  Virology and Immunology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, Egypt

• Rabab A. Moussa

  Pathology Department, Faculty of Medicine, Minia University, Minia, Egypt

• Eman E. Farghal

  Clinical Pathology Department, Faculty of Medicine, Tanta University, Tanta, AL Gharbia, Egypt

• Asmaa Mohamed Elkady

  Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Tanta University, Tanta, AL Gharbia, Egypt

Introduction: BRCA mutation status plays a pivotal role in determining sensitivity to PARP inhibitors. however, its influence on the clinical benefit derived from Bevacizumab remains less clearly established. This study aims to assess survival outcomes of Bevacizumab in advanced high-grade serous ovarian cancer (HGSOC) based on BRCA mutation status.

Methods: The study included 101 patients with advanced HGSOC who were diagnosed and treated at Tanta University Hospital. All patients were tested for BRCA1/2 mutations. Patients received six cycles of weekly carboplatin and paclitaxel, with or without Bevacizumab, followed by maintenance Bevacizumab. Patients were categorized into two groups based on whether they received Bevacizumab or not, and were further stratified according to BRCA mutation status.

Results: Bevacizumab significantly improved progression-free survival (PFS) among patients with BRCA wild-type tumors (median PFS was 24.0 months versus 18.0 months, HR (95% CI: 0.1764 (0.07581 to 0.4103), P = 0.012). BRCA-mutated patients did not show a significant PFS advantage (median PFS 23 vs. 20 months, P = 0.111). OS did not differ significantly with the use of Bevacizumab, either in the BRCA wild-type or mutated group. Univariate analysis identified FIGO stage and residual tumor (RT) as significant predictors of PFS. In the multivariate model, only the residual tumor remained significant. For OS, the FIGO stage was the sole significant factor.

Conclusion: Bevacizumab added a significant PFS advantage in BRCA wild-type patients, while patients with BRCA mutations did not achieve the same benefit, suggesting that Bevacizumab may be prioritized for BRCA wild-type patients.

[1] de Nonneville A, Kalbacher E, Cannone F, Guille A, Adelaïde J, Finetti P, et al. Endometrioid ovarian carcinoma landscape: pathological and molecular characterization. Mol Oncol 2024; 18: 2586-600.

[2] Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609-15.

[3] Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24: 24-32.

[4] Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003; 21: 3194-200.

[5] Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011; 365: 73-83.

[6] Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011; 365: 2484-96.

[7] Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med 2018; 379: 2495-505.

[8] González-Martín A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, et al. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med 2019; 381: 2391-402.

[9] Zhang M, Zhu J, Bao Y, Ao Q, Mao X, Qiu Z, et al. Bevacizumab in ovarian cancer therapy: current advances, clinical challenges, and emerging strategies. Front Bioeng Biotechnol 2025; 13: 15-89.

[10] Ferriss JS, Java JJ, Bookman MA, Fleming GF, Monk BJ, Walker JL, et al. Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG Oncology/GOG study. Gynecol Oncol 2015; 139: 17-22.

[11] Tewari KS, Burger RA, Enserro D, Norquist BM, Swisher EM, Brady MF, et al. Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer. J Clin Oncol 2019; 37: 2317-28.

[12] Harter P, Johnson T, Berton-Rigaud D, Park SY, Friedlander M, Del Campo JM, et al. BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study. Gynecol Oncol 2016; 140: 443-9.

[13] Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, et al. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. N Engl J Med 2019; 381: 2416-28.

[14] Lorusso D, Marchetti C, Conte C, Giudice E, Bolomini G, Vertechy L, et al. Bevacizumab as maintenance treatment in BRCA mutated patients with advanced ovarian cancer: A large, retrospective, multicenter case-control study. Gynecol Oncol 2020; 159: 95-100.

[15] Norquist BM, Brady MF, Harrell MI, Walsh T, Lee MK, Gulsuner S, et al. Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study. Clin Cancer Res 2018; 24: 777-83.

[16] Walsh C. Genetic Implications for Cancer Management: The Changing Landscape of Poly (ADP-ribose) Polymerase Inhibitor Indications in the Treatment of Ovarian Cancer. Clin Obstet Gynecol 2024; 67: 711-9.

[17] Administration DOHAHSFaD. 89 FR 20982 - Clovis Oncology, Inc., AstraZeneca Pharmaceuticals LP, and GlaxoSmithKline LLC; Withdrawal of Approval of the Indications for Advanced Ovarian Cancer for Poly (ADP-Ribose) Polymerase Inhibitors RUBRACA (Rucaparib) Tablets, LYNPARZA (Olaparib) Tablets, and ZEJULA (Niraparib) Capsules: Office of the Federal Register, National Archives and Records Administration; 2024 [Available from: https://www.federalregister.gov/documents/2024/03/26/202406299/.

[18] Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol 2015; 16: 928-36.

[19] Harter P, Mouret-Reynier MA, Pignata S, Cropet C, González-Martin A, Bogner G, et al. Phase III PAOLA-1/ENGOT-ov25 trial: olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer treated with platinum-based chemotherapy plus bevacizumab. Int J Gynecol Cancer 2019; 29: 66-78.

[20] Vergote I, Ray-Coquard I, Anderson DM, Cantuaria G, Colombo N, Garnier-Tixidre C, et al. Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer. Eur J Cancer 2021; 157: 415-23.

[21] Farolfi A, Lorusso D, Pignata S, De Giorgi U. Bevacizumab As Maintenance Treatment in Patients With Ovarian Cancer: Wait for BRCA Testing. J Clin Oncol 2020; 38: 172-3.

[22] Mirza MR, Åvall Lundqvist E, Birrer MJ, dePont Christensen R, Nyvang GB, Malander S, et al. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial. Lancet Oncol 2019; 20: 1409-19.

[23] Nelson BH. New insights into tumor immunity revealed by the unique genetic and genomic aspects of ovarian cancer. Curr Opin Immunol 2015; 33: 93-100.

[24] Farolfi A, Petrone M, Scarpi E, Gallà V, Greco F, Casanova C, et al. Inflammatory Indexes as Prognostic and Predictive Factors in Ovarian Cancer Treated with Chemotherapy Alone or Together with Bevacizumab. A Multicenter, Retrospective Analysis by the MITO Group (MITO 24). Target Oncol 2018; 13: 469-79.

[25] Oza AM, Lisyanskaya A, Fedenko A, de Melo AC, Shparyk Y, Rakhmatullina I, et al. Rucaparib versus chemotherapy for treatment of relapsed ovarian cancer with deleterious BRCA1 or BRCA2 mutation (ARIEL4): final results of an international, open-label, randomised, phase 3 trial. Lancet Oncol 2025; 26: 249-64.

[26] Iii C, Scambia G, Valencia R, Colombo N, Cibula D, Bidziński M, et al. LB001/#1731 Late-breaking abstract presentation: overall survival by number of prior lines of chemotherapy in patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer receiving olaparib treatment or non-platinum chemotherapy in SOLO3. Int J Gynecol Cancer 2022; 32: 6-66.

[27] Health Care Provider Letter. Zejula (Niraparib) Important Drug Warning For The Maintenance Treatment In Recurrent Ovarian Cancer (2L+): GSK; 2022 [Available from: https://www.zejulahcp.com.

[28] Cohn DE, Kim KH, Resnick KE, O'Malley DM, Straughn JM, Jr. At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis. J Clin Oncol 2011; 29: 1247-51.

[29] Gonzalez R, Havrilesky LJ, Myers ER, Secord AA, Dottino JA, Berchuck A, et al. Cost-effectiveness analysis comparing “PARP inhibitors-for-all” to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancer. Gynecol Oncol 2020; 159: 483-90.

[30] Hinde S, Epstein D, Cook A, Embleton A, Perren T, Sculpher M. The Cost-Effectiveness of Bevacizumab in Advanced Ovarian Cancer Using Evidence from the ICON7 Trial. Value Health 2016; 19: 431-9.

• PDF

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.